POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.24.2021, 10:46am CEST, WHO):   U.S. 12,874    India 50,848    Brazil 87,822    Turkey 6,143    Russia 17,594    The United Kingdom 11,481    Argentina 21,387    Columbia 28,616    Spain 1,799    Germany 1,016    Iran 11,059    Mexico 4,233    Peru 2,995    Indonesia 15,308    South Africa 11,093    Chile 2,746    Philippines 4,353    Iraq 6,297    Bangladesh 5,727    Portugal 1,020    Japan 1,790    Malaysia 5,244    Nepal 1,511    United Arab Emirates 1,988    Saudi Arabia 1,253    Ecuador 1,931    Bolivia 1,667    Paraguay 1,746    Panama 1,208    Tunisia 3,638    Uruguay 2,079    Costa Rica 1,525    Kuwait 1,870    Venezuela 1,334    Oman 2,047    Sri Lanka 2,196    Thailand 3,174    Cuba 2,055    Zambia 3,028    Afghanistan 1,575    Mongolia 2,213    Rwanda 1,483    Réunion 1,061    China 122    Singapore 22    New Zealand 0    Australia 12    South Korea 610   

South Korea conditionally approves first domestic COVID-19 treatment

Christian Fernsby |
South Korea's drug safety agency said Friday that it conditionally approved the country's first homegrown COVID-19 treatment candidate, developed by local pharmaceutical giant Celltrion.

Article continues below

Topics: SOUTH KOREA   

The Ministry of Food and Drug Safety said in a statement that it granted a marketing authorization for Regkirona Inj. 960mg (regdanvimab) on condition of submitting the results of a global phase-three clinical trial.

Celltrion made the application to the agency on Dec. 29, and announced the results in January from a global phase-two clinical study.

Regkirona Inj. is a recombinant neutralizing antibody drug, produced by selecting a neutralizing antibody gene in a COVID-19 convalescent patient's blood and inserting the selected gene into a host cell that is cultured for the large-scale production of the antibody.

The treatment candidate can be administered to COVID-19 outpatients with mild symptoms at high risk, which refer to people aged over 60 years or with more than one underlying disease among cardiovascular risk, diabetes, high blood pressure and chronic respiratory disease, as well as outpatients with moderate symptoms aged 18 or higher.

It can be administered by intravenous infusion that is directly injected into the vein for about 90 minutes.

The drug safety agency said Regkirona Inj. was the first approved COVID-19 treatment as a domestically-developed drug and the third regulatory-verified COVID-19 antibody treatment in the world.

It added that the use of the drug along with other vaccines can help combat the COVID-19 pandemic.

What to read next

Biopsies during early treatment predict response to melanoma immunotherapy
Three-minute brain stimulation therapy effective for hard-to-treat depression
Wuhan coronavirus: South Korea reviewing plans to import Japanese antiviral drug